《大行報告》大和升藥明生物(02269.HK)評級至「買入」 目標價下調至72元
大和發表研究報告指,自2月起藥明生物(02269.HK)被列入美國未經核實實體名單以來,股價已調整超過 50%,認為目前已充分反映負面消息及市場疲弱情緒的影響,估值具吸引力,加上近期中美關係相對改善,料將推動股價反彈。
該行表示,注意到中共中央政治局委員楊潔篪與美國國家安全顧問沙利文近日會面,認為目前中美緊張局勢已經緩和,考慮到藥明來自北美市場的收入佔比達約50% ,認為中美關係改善將顯著提振市場情緒,進而推高公司股價,將投資評級由「跑贏大市」升至「買入」。
惟大和指出,未經核實實體名單相關因素尚未完全消除,因此將今年每股盈利預測下調2%至1元人民幣,目標價從75元下調至72元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.